Mar 8 2010
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of
advanced image analysis and workflow solutions for the early
identification of cancer, announces that the United States Patent and
Trademark Office recently granted the company Patent Number 7,660,448.
This patent covers future iterations of iCAD’s SecondLook®
Digital Computer-Aided Detection (CAD) solution with potential
application to the company’s other image analysis solutions. iCAD has
developed and now patented this technology, which incorporates CAD
lesion metrics to provide clinicians with enhanced clinical information.
“Advancements covered by this new patent will
incorporate CAD lesion metrics that can provide clinicians with insight
into the system’s decision making process.”
“iCAD’s R&D teams are continually striving to provide the most
sophisticated image analysis solutions that incorporate feedback from
our global customer base of radiology professionals,” said Ken Ferry,
President and CEO of iCAD. “Advancements covered by this new patent will
incorporate CAD lesion metrics that can provide clinicians with insight
into the system’s decision making process.”
iCAD was also recently granted a U.S. patent for a Computed Tomography
(CT) image analysis software development. This patent was developed to
improve the way CT image analysis solutions can assess data
three-dimensionally.
These patents are included among iCAD’s broad patent portfolio that is
based on years of research and development on its image analysis
solutions for existing and new product applications. iCAD currently has
27 granted U.S. patents and 15 U.S. patent applications pending.
About iCAD, Inc.
Researchers uncover key genes linked to DCIS progression